In the Press
March 9, 2020

Public Health Crises and FDA Scrutiny (PM 360)

Every public health emergency or outbreak brings with it a corresponding urgent need for medical products to address the emerging crisis, and the 2019 novel coronavirus (coined COVID-19 by WHO) is no different. Product developers and marketers are quick to assess in such crises whether their products on the market or in development have utility or can play a role in addressing the crises. Goodwin’s Julie Tibbets, a partner in the Technology and Life Sciences group, and Steven Tjoe, an associate in the same group, discuss how public health crises bring added regulatory enforcement scrutiny to products in the marketplace. Read the by-line here.